Eltrombopag: Role in Cytopenias Following Hematopoietic Stem Cell Transplantation

Overview

Journal Indian J Hematol Blood Transfus

Specialty Hematology

Date 2020 May 20

PMID 32425372

Citations 3

Authors

Ram Vasudevan Nampoothiri

Rajat Kumar

Affiliations

Soon will be listed here.

Abstract

Eltrombopag is a small molecule oral agonist of the thrombopoietin receptor. Initially used for improving thrombocytopenia in chronic immune thrombocytopenia (ITP), it was later found to be efficacious in various other etiologies of thrombocytopenia as well as inherited marrow failure syndromes. Lately, it has been used for thrombocytopenia and poor graft function after allogeneic hematopoietic stem cell transplantation (HSCT) without any severe adverse events. Although prospective evidence of the efficacy is limited, there are increasing reports on the safety and efficacy with Eltrombopag in post HSCT thrombocytopenia and poor graft function. This provides an exciting opportunity for further research to evaluate both efficacy and cost-effectiveness of the use of Eltrombopag in this scenario. Here we review the current evidence on the indications for the use of Eltrombopag in the post allogeneic hematopoietic stem cell transplant setting.

Citing Articles

Eltrombopag Enhances Recovery from Cytopenias Due to Poor Graft Function after Hematopoietic Cell Transplantation.

Halahleh K, Al-YaGoub M, Makoseh M, Al-Far R, Dana W, Pharm R Blood Cell Ther. 2025; 8(1):160-166.

PMID: 40061175 PMC: 11883521. DOI: 10.31547/bct-2024-017.

Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function.

Arslan Davulcu E, Soyer N, Vural F Cureus. 2023; 15(9):e44555.

PMID: 37790070 PMC: 10544786. DOI: 10.7759/cureus.44555.

Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantation.

Karatas A, Goker H, Demiroglu H, Malkan U, Velet M, Cinar O Turk J Med Sci. 2022; 52(2):413-419.

PMID: 36161632 PMC: 10381231. DOI: 10.55730/1300-0144.5328.

Eltrombopag post autologous hematopoietic stem cell transplant - an emerging indication in younger pediatric patients.

Gupta A, Srinivasan P, Das G, Meena J, Tanwar P, Seth R Am J Blood Res. 2021; 11(2):168-171.

PMID: 34079631 PMC: 8165717.

References

Desmond R, Townsley D, Dumitriu B, Olnes M, Scheinberg P, Bevans M . Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2013; 123(12):1818-25. PMC: 3962161. DOI: 10.1182/blood-2013-10-534743. View

Bao W, Bussel J, Heck S, He W, Karpoff M, Boulad N . Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010; 116(22):4639-45. PMC: 2996119. DOI: 10.1182/blood-2010-04-281717. View

Reid R, Bennett J, Becker M, Chen Y, Milner L, Phillips 2nd G . Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia. Am J Hematol. 2012; 87(7):743-5. DOI: 10.1002/ajh.23225. View

Zhao Z, Sun Q, Sokoll L, Streiff M, Cheng Z, Grasmeder S . Eltrombopag mobilizes iron in patients with aplastic anemia. Blood. 2018; 131(21):2399-2402. PMC: 5969382. DOI: 10.1182/blood-2018-01-826784. View

Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong R, Anagnostopoulos A . Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol. 2017; 5(1):e34-e43. DOI: 10.1016/S2352-3026(17)30228-4. View

Imbach P, Crowther M . Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011; 365(8):734-41. DOI: 10.1056/NEJMct1014202. View

Ahmed S, Bashir Q, Bassett R, Poon M, Valdez B, Konoplev S . Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021; 27(5):430.e1-430.e7. DOI: 10.1016/j.jtct.2021.02.004. View

Marotta S, Marano L, Ricci P, Cacace F, Frieri C, Simeone L . Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplant. 2019; 54(8):1346-1353. DOI: 10.1038/s41409-019-0442-3. View

Davies S, Kollman C, Anasetti C, Antin J, Gajewski J, Casper J . Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000; 96(13):4096-102. View

10.

Alvarado L, Huntsman H, Cheng H, Townsley D, Winkler T, Feng X . Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood. 2019; 133(19):2043-2055. PMC: 6509545. DOI: 10.1182/blood-2018-11-884486. View

11.

Stasia A, Ghiso A, Galaverna F, Raiola A, Gualandi F, Luchetti S . CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(9):1440-3. DOI: 10.1016/j.bbmt.2014.05.016. View

12.

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S . Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016; 22(5):919-24. DOI: 10.1016/j.bbmt.2016.01.018. View

13.

Tonelli R, Scardovi A, Pession A, Strippoli P, Bonsi L, Vitale L . Compound heterozygosity for two different amino-acid substitution mutations in the thrombopoietin receptor (c-mpl gene) in congenital amegakaryocytic thrombocytopenia (CAMT). Hum Genet. 2000; 107(3):225-33. DOI: 10.1007/s004390000357. View

14.

. The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Poster Session. Bone Marrow Transplant. 2019; 54(Suppl 1):144-619. PMC: 7091813. DOI: 10.1038/s41409-019-0559-4. View

15.

Schifferli A, Kuhne T . Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?. Semin Hematol. 2016; 53 Suppl 1:S31-4. DOI: 10.1053/j.seminhematol.2016.04.010. View

16.

Yamazaki R, Kuwana M, Mori T, Okazaki Y, Kawakami Y, Ikeda Y . Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. Bone Marrow Transplant. 2006; 38(5):377-84. DOI: 10.1038/sj.bmt.1705444. View

17.

McHutchison J, Dusheiko G, Shiffman M, Rodriguez-Torres M, Sigal S, Bourliere M . Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007; 357(22):2227-36. DOI: 10.1056/NEJMoa073255. View

18.

Dyba J, Tinmouth A, Bredeson C, Matthews J, Allan D . Eltrombopag after allogeneic haematopoietic cell transplantation in a case of poor graft function and systematic review of the literature. Transfus Med. 2016; 26(3):202-7. DOI: 10.1111/tme.12300. View

19.

Jenkins J, Williams D, Deng Y, Uhl J, Kitchen V, Collins D . Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007; 109(11):4739-41. DOI: 10.1182/blood-2006-11-057968. View

20.

Bruno B, Gooley T, Sullivan K, Davis C, Bensinger W, Storb R . Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(3):154-62. DOI: 10.1053/bbmt.2001.v7.pm11302549. View